Heart Failure Drug Sacubitril/Valsartan Protects Against Parkinson's by Boosting Natriuretic Peptides
Sacubitril/valsartan protected dopaminergic neurons in a Parkinson's rat model by inhibiting neprilysin to boost natriuretic peptide levels, activating the neuroprotective WNT/β-catenin pathway.
Quick Facts
What This Study Found
SAC/VAL was more neuroprotective than VAL alone in PD rats, likely through neprilysin inhibition boosting natriuretic peptides that activate the WNT/β-catenin pathway, while reducing oxidative stress and neuroinflammation.
Key Numbers
How They Did This
Rotenone-induced PD model in male Wistar rats, with oral SAC/VAL (40 mg/kg/day) or VAL (20 mg/kg/day) for 6 weeks, assessing behavior, dopaminergic injury, DA/TH/NP levels, WNT/β-catenin pathway, and oxidative/inflammatory markers.
Why This Research Matters
Drug repurposing an approved heart failure medication for Parkinson's would be much faster and cheaper than developing new drugs. The natriuretic peptide mechanism provides a novel neuroprotective pathway.
The Bigger Picture
This reveals that natriuretic peptides have neuroprotective properties beyond cardiovascular function, and that neprilysin inhibition (by boosting these peptides) could be a novel therapeutic strategy for neurodegeneration.
What This Study Doesn't Tell Us
Rat model; rotenone-induced PD doesn't fully replicate human PD. Cannot separate all effects of SAC from VAL. Dosing may not translate directly to humans. Short treatment duration.
Questions This Raises
- ?Should heart failure patients on SAC/VAL be monitored for reduced PD risk?
- ?Could natriuretic peptides be directly administered as neuroprotective agents?
- ?Would SAC/VAL show benefits in human PD patients in a clinical trial?
Trust & Context
- Key Stat:
- SAC/VAL > VAL alone The neprilysin inhibitor component (sacubitril) provided additional neuroprotection beyond the angiotensin blocker alone
- Evidence Grade:
- Well-controlled preclinical study with SAC/VAL vs VAL comparison enabling attribution of effects to neprilysin inhibition. Strong rationale for clinical investigation.
- Study Age:
- Published in 2025.
- Original Title:
- The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model.
- Published In:
- Neuropharmacology, 283, 110734 (2026)
- Database ID:
- RPEP-15140
Evidence Hierarchy
Frequently Asked Questions
How does a heart failure drug help Parkinson's?
Sacubitril blocks neprilysin, an enzyme that breaks down natriuretic peptides. When these peptides build up, they activate a protective brain pathway (WNT/β-catenin) that helps dopaminergic neurons survive — the neurons that die in Parkinson's.
Could patients already on this drug be getting brain protection?
It's possible. Heart failure patients taking sacubitril/valsartan might already be getting some neuroprotective benefit. Studying PD rates in these patients could provide early evidence.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15140APA
Elkhial, Rania Tarek; Awny, Magdy M; El-Sayed, Elsayed K; Nofal, Shahira. (2026). The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model.. Neuropharmacology, 283, 110734. https://doi.org/10.1016/j.neuropharm.2025.110734
MLA
Elkhial, Rania Tarek, et al. "The enhanced Wnt/β-catenin pathway upregulation by sacubitril/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model.." Neuropharmacology, 2026. https://doi.org/10.1016/j.neuropharm.2025.110734
RethinkPeptides
RethinkPeptides Research Database. "The enhanced Wnt/β-catenin pathway upregulation by sacubitri..." RPEP-15140. Retrieved from https://rethinkpeptides.com/research/elkhial-2026-the-enhanced-wntcatenin-pathway
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.